 Home > Active Ingredient News > Drugs Articles > Express US$3.3 billion to accelerate RNAi therapy development, Novo Nordisk will acquire Dicerna

Express US$3.3 billion to accelerate RNAi therapy development, Novo Nordisk will acquire Dicerna

 Last Update: 2021-12-05
 Source: Internet
 Author: User

Tags

diet ibs patients

magnetic field therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 18, 2021, Dicerna Pharmaceuticals, which focuses on the development of RNAi therapy, announced that it has reached a final agreement with Novo Nordisk
.

Novo Nordisk will spend approximately US$3.

Speed up Novo Nordisk's RNAi drug development and expand the application of RNAi technology

Since 2019, Novo Nordisk and Dicerna have been research partners, using Dicerna's proprietary GalXC RNAi platform technology to discover and develop RNAi therapies
.

The cooperation between Novo Nordisk and Dicerna includes the exploration of more than 30 hepatocyte targets, which may provide more for diseases including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.

RNAi therapy reduces the expression of disease-causing proteins by targeting and silencing mRNA that directs protein synthesis
.

It can be used to target disease-causing genes that cannot be reached by conventional antibodies and small molecule drugs

Dicerna's technology platform can effectively deliver therapies to multiple tissues such as the liver, central nervous system, muscles, etc.

▲Dicerna's RNAi technology platform (picture source: Dicerna official website)

Mr.
Marcus Schindler, Executive Vice President and Chief Scientific Officer of Novo Nordisk, said: “The acquisition of Dicerna has accelerated Novo Nordisk’s research in the field of RNAi and expanded the use of RNAi technology
.

Dicerna’s RNAi drug development engine and intracellular delivery Combining technology with our understanding of disease biology and our deep ability to target tissues through peptides and proteins, we may expand our R&D pipeline to patients with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH, as well as endocrine disorders and Patients with rare diseases such as bleeding disorders provide life-changing precision medicines

Original English: https://investors.

dicerna.
com/news-releases/news-release-details/novo-nordisk-acquire-dicerna

Original English: https://investors.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.